Novel oral anticoagulants for stroke prevention in the geriatric population

Daniel Kim, Richard Barna, Mary Barna Bridgeman, Luigi Brunetti

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.

Original languageEnglish (US)
Pages (from-to)15-29
Number of pages15
JournalAmerican Journal of Cardiovascular Drugs
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2014

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Novel oral anticoagulants for stroke prevention in the geriatric population'. Together they form a unique fingerprint.

  • Cite this